Surgeon General's Workshop on Deep Vein ThrombosisPanel 6: STRATEGIES TO IMPROVE THE USE OF VTE
PROPHYLAXIS
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Intervention n = 1255 |
Control n = 1251 |
P value |
|
|---|---|---|---|
| Overall |
421 (33.5) |
182 (14.5) |
< 0.001 |
| Mechanical |
125 (10.0) |
19 (1.5) |
< 0.001 |
| GCS |
52 (4.1) |
7 (0.6) |
< 0.001 |
| IPC |
73 (5.8) |
12 (1.0) |
< 0.001 |
| Pharmacologic |
296 (23.6) |
163 (13.0) |
< 0.001 |
| Heparin |
213 (17.0) |
81 (6.5) |
< 0.001 |
| Warfarin |
28 (2.2) |
41 (3.3) |
0.11 |
| Enoxaparin |
55 (4.4) |
41 (3.3) |
0.18 |
| (Kucher N, et al. NEJM 2005;352:969-977) | |||
SLIDE 10: PRIMARY END POINT: 90 DAYS
| Intervention (n = 1255) |
Control (n = 1251) |
Hazard ratio (95% CI) |
P | |
|---|---|---|---|---|
| Total VTE | 61 (4.9) | 103 (8.2) | 0.59 (0.43–0.81) | 0.001 |
| Acute PE | 14 (1.1) | 35 (2.8) | 0.40 (0.21–0.74) | 0.004 |
| Prox. DVT | 10 (0.8) | 23 (1.8) | 0.47 (0.20–1.09) | 0.08 |
| Distal DVT | 5 (0.4) | 12 (1.0) | 0.42 (0.15–1.18) |
0.10 |
| UE DVT | 32 (2.5) | 33 (2.6) | 0.97 (0.60–1.58) | 0.90 |
Line chart showing intervention and control primary end points. The primary end point of symptomatic and imaging-confirmed DVT or pulmonary embolism occurred in 61 intervention-group and 103 control-group patients. At 90 days, the intervention strategy reduced the risk of DVT or pulmonary embolism by 41%
SLIDE 12: RISK SCORE AND PROPHYLAXIS
|
Present Cohort n(%) |
Historical Intervention n(%) |
p |
|
|---|---|---|---|
| Patients at risk of VTE with alert sent | 411 (7%) | 1255 (18%) | p <0.001 |
| Services | |||
| Medical | 330 (80) | 1038 (82) | p=0.30 |
| Surgical | 81 (19) | 217 (17) | p=0.30 |
| Cumulative Risk Score | |||
| 4 | 266 (64) | 792 (63) | p=0.60 |
| 5 | 101 (24) | 327 (26) | p=0.60 |
| 6 | 37 (9) | 110 (9) | p=0.96 |
| 7 | 7 (1) | 22 (2) | p=0.88 |
| 8 | 0 (0) | 4 (0.3) | p=0.57 |
| Prophylaxis Prescribed | 166 (40%) | 421 (34%) | p=0.01 |
SLIDE 13: VTE PROPHYLAXIS: THE FUTURE